tradingkey.logo
tradingkey.logo
Search

Caris Life Sciences Inc

CAI
Add to Watchlist
17.820USD
-0.500-2.73%
Close 06/30, 16:00ETQuotes delayed by 15 min
5.04BMarket Cap
LossP/E TTM

TradingKey Stock Score of Caris Life Sciences Inc

Currency: USD Updated: 2026-06-29

Key Insights

Caris Life Sciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 78 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.33.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Caris Life Sciences Inc's Score

Industry at a Glance

Industry Ranking
78 / 204
Overall Ranking
184 / 4570
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

Caris Life Sciences Inc Highlights

StrengthsRisks
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 165.26% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 812.03M.
Undervalued
The company’s latest PE is -6.63, at a low 3-year percentile range.
Held by Stanley Druckenmiller
Star Investor Stanley Druckenmiller holds 2.20M shares of this stock.

Analyst Rating

Based on 12 analysts
Buy
Current Rating
28.333
Target Price
+54.66%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

FAQs

How does TradingKey generate the Stock Score of Caris Life Sciences Inc?

The TradingKey Stock Score provides a comprehensive assessment of Caris Life Sciences Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Caris Life Sciences Inc’s performance and outlook.

How do we generate the financial health score of Caris Life Sciences Inc?

To generate the financial health score of Caris Life Sciences Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Caris Life Sciences Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Caris Life Sciences Inc.

How do we generate the company valuation score of Caris Life Sciences Inc?

To generate the company valuation score of Caris Life Sciences Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Caris Life Sciences Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Caris Life Sciences Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Caris Life Sciences Inc.

How do we generate the earnings forecast score of Caris Life Sciences Inc?

To calculate the earnings forecast score of Caris Life Sciences Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Caris Life Sciences Inc’s future.

How do we generate the price momentum score of Caris Life Sciences Inc?

When generating the price momentum score for Caris Life Sciences Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Caris Life Sciences Inc’s prices. A higher score indicates a more stable short-term price trend for Caris Life Sciences Inc.

How do we generate the institutional confidence score of Caris Life Sciences Inc?

To generate the institutional confidence score of Caris Life Sciences Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Caris Life Sciences Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Caris Life Sciences Inc.

How do we generate the risk management score of Caris Life Sciences Inc?

To assess the risk management score of Caris Life Sciences Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Caris Life Sciences Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Caris Life Sciences Inc.
KeyAI